AVS Raises $20 Million in Series B Round to Advance Pulsatile Intravascular Lithotripsy (PIVL) Solutions
The new funding will accelerate clinical trial timelines for the company’s device for peripheral application in pulsatile intravascular lithotripsy (PIVL) cases and advance development and preclinical work on a PIVL device for coronary cases.
- The new funding will accelerate clinical trial timelines for the company’s device for peripheral application in pulsatile intravascular lithotripsy (PIVL) cases and advance development and preclinical work on a PIVL device for coronary cases.
- BioStar Capital, the lead investor in the company’s Series A round, also led the Series B round.
- BioStar Capital is focused on transformational investments in medical technologies with an emphasis on cardiovascular and orthopedics.
- “We are proud to support AVS in both its successful Series A and Series B funding rounds,” said Louis Cannon, MD Founder and Senior Managing Partner of BioStar Capital.